Homepage
Author:
Edison Oncology Holding Corp.
Posted Date:
June 1, 2026
Edison Oncology Presents EO1001 Trials-in-Progress Poster at ASCO 2026, Highlighting Differentiated Activity in EGFR Extracellular Domain Mutant Cancers with No Approved Targeted Therapy
Edison Oncology Holding Corp.
June 1, 2026
Edison Oncology Presents New Preclinical Data on EO1001 and EO4426 Highlighting Differentiated Targeting of Cancer Resistance Pathways at AACR 2026
Edison Oncology Holding Corp.
April 23, 2026
Edison Oncology Completes Target Enrollment in Phase 1/2a Orotecan(TM) Clinical Trial
Edison Oncology Holding Corp.
March 20, 2026
Edison Oncology to Present Two Posters at the 2026 AACR Annual Meeting
Edison Oncology Holding Corp.
March 18, 2026
